CoChat

Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials

Open access

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Intensive blood pressure (BP) treatment can avert cardiovascular disease (CVD) events but can cause some serious adverse events. We sought to develop and validate risk models for predicting absolute risk difference (increased risk or decreased risk) for CVD events and serious adverse events from intensive BP therapy. A secondary aim was to test if the statistical method of elastic net regularization would improve the estimation of risk models for predicting absolute risk difference, as compared to a traditional backwards variable selection approach. METHODS AND FINDINGS: Cox models were derived from SPRINT trial data and validated on ACCORD-BP trial data to estimate risk of CVD events and serious adverse events; the models included terms for intensive BP treatment and heterogeneous response to intensive treatment. The Cox models were then used to estimate the absolute reduction in probability of CVD events (benefit) and absolute increase in probability of serious adverse events (harm) for each individual from intensive treatment. We compared the method of elastic net regularization, which uses repeated internal cross-validation to select variables and estimate coefficients in the presence of collinearity, to a traditional backwards variable selection approach. Data from 9,069 SPRINT participants with complete data on covariates were utilized for model development, and data from 4,498 ACCORD-BP participants with complete data were utilized for model validation. Participants were exposed to intensive (goal systolic pressure < 120 mm Hg) versus standard (<140 mm Hg) treatment. Two composite primary outcome measures were evaluated: (i) CVD events/deaths (myocardial infarction, acute coronary syndrome, stroke, congestive heart failure, or CVD death), and (ii) serious adverse events (hypotension, syncope, electrolyte abnormalities, bradycardia, or acute kidney injury/failure). The model for CVD chosen through elastic net regularization included interaction terms suggesting that older age, black race, higher diastolic BP, and higher lipids were associated with greater CVD risk reduction benefits from intensive treatment, while current smoking was associated with fewer benefits. The model for serious adverse events chosen through elastic net regularization suggested that male sex, current smoking, statin use, elevated creatinine, and higher lipids were associated with greater risk of serious adverse events from intensive treatment. SPRINT participants in the highest predicted benefit subgroup had a number needed to treat (NNT) of 24 to prevent 1 CVD event/death over 5 years (absolute risk reduction [ARR] = 0.042, 95% CI: 0.018, 0.066; P = 0.001), those in the middle predicted benefit subgroup had a NNT of 76 (ARR = 0.013, 95% CI: -0.0001, 0.026; P = 0.053), and those in the lowest subgroup had no significant risk reduction (ARR = 0.006, 95% CI: -0.007, 0.018; P = 0.71). Those in the highest predicted harm subgroup had a number needed to harm (NNH) of 27 to induce 1 serious adverse event (absolute risk increase [ARI] = 0.038, 95% CI: 0.014, 0.061; P = 0.002), those in the middle predicted harm subgroup had a NNH of 41 (ARI = 0.025, 95% CI: 0.012, 0.038; P < 0.001), and those in the lowest subgroup had no significant risk increase (ARI = -0.007, 95% CI: -0.043, 0.030; P = 0.72). In ACCORD-BP, participants in the highest subgroup of predicted benefit had significant absolute CVD risk reduction, but the overall ACCORD-BP participant sample was skewed towards participants with less predicted benefit and more predicted risk than in SPRINT. The models chosen through traditional backwards selection had similar ability to identify absolute risk difference for CVD as the elastic net models, but poorer ability to correctly identify absolute risk difference for serious adverse events. A key limitation of the analysis is the limited sample size of the ACCORD-BP trial, which expanded confidence intervals for ARI among persons with type 2 diabetes. Additionally, it is not possible to mechanistically explain the physiological relationships explaining the heterogeneous treatment effects captured by the models, since the study was an observational secondary data analysis. CONCLUSIONS: We found that predictive models could help identify subgroups of participants in both SPRINT and ACCORD-BP who had lower versus higher ARRs in CVD events/deaths with intensive BP treatment, and participants who had lower versus higher ARIs in serious adverse events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1002410

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Flow of SPRINT trial participants (derivation cohort) and ACCORD-BP participants (validation cohort) into the current study. Note that a large number of ACCORD-BP participants were deemed ineligible for the blood pressure study because the ACCORD trial had a factorial design in which all participants were randomized to intensive versus standard glycemic treatment, and only a subset of participants was additionally randomized to intensive versus standard blood pressure treatment (the other subset was additionally randomized to intensive versus standard lipid treatment).
Fig 1 Flow of SPRINT trial participants (derivation cohort) and ACCORD-BP participants (validation cohort) into the current study. Note that a large number of ACCORD-BP participants were deemed ineligible for the blood pressure study because the ACCORD trial had a factorial design in which all participants were randomized to intensive versus standard glycemic treatment, and only a subset of participants was additionally randomized to intensive versus standard blood pressure treatment (the other subset was additionally randomized to intensive versus standard lipid treatment).CC BY · PubMed Central
Fig 2 Calibration plots for models fit by elastic net regularization versus traditional backwards selection. Calibration plots showing the relationship between Cox-model-predicted Kaplan–Meyer event probabilities for each of the outcomes versus average observed Kaplan–Meyer event probabilities for each decile of risk in SPRINT and in ACCORD-BP. All deciles had >5 events observed per group. Diagonal lines show the perfect expected versus observed slope of 1. Note that the models required recalibration of the baseline Cox model hazard rate to fit the ACCORD-BP data (see main text and Table 2), although model coefficients were not adjusted for assessments. (A) CVD events/deaths by elastic net regularization. (B) Serious adverse events by elastic net regularization. (C) CVD events/deaths by traditional backwards selection. (D) Serious adverse events by traditional backwards selection. CVD, cardiovascular disease.
Fig 2 Calibration plots for models fit by elastic net regularization versus traditional backwards selection. Calibration plots showing the relationship between Cox-model-predicted Kaplan–Meyer event probabilities for each of the outcomes versus average observed Kaplan–Meyer event probabilities for each decile of risk in SPRINT and in ACCORD-BP. All deciles had >5 events observed per group. Diagonal lines show the perfect expected versus observed slope of 1. Note that the models required recalibration of the baseline Cox model hazard rate to fit the ACCORD-BP data (see main text and Table 2), although model coefficients were not adjusted for assessments. (A) CVD events/deaths by elastic net regularization. (B) Serious adverse events by elastic net regularization. (C) CVD events/deaths by traditional backwards selection. (D) Serious adverse events by traditional backwards selection. CVD, cardiovascular disease.CC BY · PubMed Central
Fig 3 Predicted benefit and predicted harm from intensive blood pressure therapy based on models fit by elastic net regularization. Scatterplot of predictive benefit and predicted harm with intensive blood pressure therapy among SPRINT participants (blue) and ACCORD-BP participants (orange), based on the Cox hazards models. The figure reveals wide variation in predicted benefit and predicted harm within both participant samples, but overall centering at lower predicted benefit and higher predicted harm for the ACCORD-BP participant sample. CVD, cardiovascular disease; int Rx, intensive treatment.
Fig 3 Predicted benefit and predicted harm from intensive blood pressure therapy based on models fit by elastic net regularization. Scatterplot of predictive benefit and predicted harm with intensive blood pressure therapy among SPRINT participants (blue) and ACCORD-BP participants (orange), based on the Cox hazards models. The figure reveals wide variation in predicted benefit and predicted harm within both participant samples, but overall centering at lower predicted benefit and higher predicted harm for the ACCORD-BP participant sample. CVD, cardiovascular disease; int Rx, intensive treatment.CC BY · PubMed Central
Fig 4 Predicted versus observed absolute risk differences in benefit and harm among SPRINT and ACCORD-BP trial participant subgroups, using predictions from the elastic net regularization model. Dotted lines show the perfect predicted versus observed slope of 1. Dark colored lines show the mean of observed absolute risk differences, while light colored lines show 95% confidence intervals. (A) SPRINT, benefit. (B) ACCORD, benefit. (C) SPRINT, harm. (D) ACCORD, harm. CVD, cardiovascular disease.
Fig 4 Predicted versus observed absolute risk differences in benefit and harm among SPRINT and ACCORD-BP trial participant subgroups, using predictions from the elastic net regularization model. Dotted lines show the perfect predicted versus observed slope of 1. Dark colored lines show the mean of observed absolute risk differences, while light colored lines show 95% confidence intervals. (A) SPRINT, benefit. (B) ACCORD, benefit. (C) SPRINT, harm. (D) ACCORD, harm. CVD, cardiovascular disease.CC BY · PubMed Central
Fig 5 Predicted versus observed absolute risk differences in benefit and harm among SPRINT and ACCORD-BP trial participant subgroups, using predictions from the traditional backwards selection model. Dotted lines show the perfect predicted versus observed slope of 1. Dark colored lines show the mean of observed absolute risk differences, while light colored lines show 95% confidence intervals. (A) SPRINT, benefit. (B) ACCORD, benefit. (C) SPRINT, harm. (D) ACCORD, harm. CVD, cardiovascular disease.
Fig 5 Predicted versus observed absolute risk differences in benefit and harm among SPRINT and ACCORD-BP trial participant subgroups, using predictions from the traditional backwards selection model. Dotted lines show the perfect predicted versus observed slope of 1. Dark colored lines show the mean of observed absolute risk differences, while light colored lines show 95% confidence intervals. (A) SPRINT, benefit. (B) ACCORD, benefit. (C) SPRINT, harm. (D) ACCORD, harm. CVD, cardiovascular disease.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 77

Metadata

Authors
Basu, S., Sussman, J. B., Rigdon, J., Steimle, L., Denton, B. T., & Hayward, R. A.
Affiliations
  • Harvard University (US)
  • University of Michigan (US)
  • Stanford University (US)
Corresponding author
Basu, Sanjay
Venue
PLOS Medicine
Published
2017-10-17
Volume
14
Issue
10
Pages
e1002410
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2766088180
Cited by
77
References
37
Citations by year
2026: 2 · 2025: 6 · 2024: 2 · 2023: 8 · 2022: 12 · 2021: 10 · 2020: 14 · 2019: 15 · 2018: 6 · 2017: 2
FWCI
7.83
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Center on Minority Health and Health Disparities (DP2MD010478)
  • National Institute on Minority Health and Health Disparities (U54MD010724)
  • National Heart, Lung, and Blood Institute (K08HL121056)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P60DK20572)
  • Center for Integrated Healthcare, U.S. Department of Veterans Affairs (IIR 11-088, CDA 13-021)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
  • Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
Keywords
intensive blood pressure treatment, cardiovascular events, serious adverse events, risk prediction model, elastic net regularization, feature selection, SPRINT trial, number needed to treat, acute kidney injury, hypotension, statin use, serum lipids, age and race differences, model validation, multicollinearity
MeSH terms
Adult, Aged, Aged, 80 and over, Antihypertensive Agents, Blood Pressure, Female, Heart Failure, Humans, Hypertension, Male, Middle Aged, Myocardial Infarction, Risk Factors, Proportional Hazards Models, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials. https://app.cochat.ai/papers/10.1371/journal.pmed.1002410
The paper
Basu, S., Sussman, J. B., Rigdon, J., Steimle, L., Denton, B. T., & Hayward, R. A. (2017). Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1002410

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.